403 related articles for article (PubMed ID: 34379968)
1. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.
Yu DA; Kim YE; Kwon O; Park H
Indian J Dermatol Venereol Leprol; 2021; 87(5):621-627. PubMed ID: 34379968
[TBL] [Abstract][Full Text] [Related]
2. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Almutairi N; Nour TM; Hussain NH
Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Liu LY; Craiglow BG; Dai F; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
[TBL] [Abstract][Full Text] [Related]
4. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
Craiglow BG; Liu LY; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
[TBL] [Abstract][Full Text] [Related]
6. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Cheng MW; Kehl A; Worswick S; Goh C
J Drugs Dermatol; 2018 Jul; 17(7):800-803. PubMed ID: 30005104
[TBL] [Abstract][Full Text] [Related]
7. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis.
Guo L; Feng S; Sun B; Jiang X; Liu Y
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):192-201. PubMed ID: 31494993
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib as a treatment of alopecia areata in adolescents.
Morales-Miranda AY; Bueno-Arias GM; Aguirre-Félix ÓG; Tovar-Franco R
Bol Med Hosp Infant Mex; 2019; 76(4):182-187. PubMed ID: 31303654
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
[TBL] [Abstract][Full Text] [Related]
10. A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata.
Deeb M; Beach RA
J Cutan Med Surg; 2017; 21(6):562-563. PubMed ID: 28635319
[TBL] [Abstract][Full Text] [Related]
11. Off-label Studies on the Use of Ruxolitinib in Dermatology.
Tegtmeyer K; Ravi M; Zhao J; Maloney NJ; Lio PA
Dermatitis; 2021 May-Jun 01; 32(3):164-172. PubMed ID: 33443378
[TBL] [Abstract][Full Text] [Related]
12. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS
J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800
[TBL] [Abstract][Full Text] [Related]
13. Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study.
Huang J; Deng S; Li J; Tang Y; Liu F; Liu Y; Rao S; Shi W
Acta Derm Venereol; 2023 Nov; 103():adv13475. PubMed ID: 37955531
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase inhibitors: An innovative treatment for alopecia areata.
Park H; Yu DA; Kwon O
J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review.
Benton S; Farah R; Freese R; Hordinsky M
Dermatol Ther; 2022 Apr; 35(4):e15310. PubMed ID: 34997820
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
[TBL] [Abstract][Full Text] [Related]
17. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.
Jabbari A; Nguyen N; Cerise JE; Ulerio G; de Jong A; Clynes R; Christiano AM; Mackay-Wiggan J
Exp Dermatol; 2016 Aug; 25(8):642-3. PubMed ID: 27119625
[No Abstract] [Full Text] [Related]
18. JAK Inhibitors for the Treatment of Pediatric Alopecia Areata.
Hamilton CE; Craiglow BG
J Investig Dermatol Symp Proc; 2020 Nov; 20(1):S31-S36. PubMed ID: 33099381
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
Wei D; Chen Y; Shen Y; Xie B; Song X
Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib.
Chen YL; Liu LX; Huang Q; Li XY; Hong XP; Liu DZ
Front Immunol; 2021; 12():654376. PubMed ID: 33936080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
